TP53 and melanoma: In the mucosal melanoma cohort, HRD was associated with significant higher TP53 mutation (34.85% v 10.38%, P < .01) with no association with BRAF (4.48% v 11.32%, P = .752) and NRAS (11.94% v 23.81%, P = .475) mutations (Fig 1D).